Germany’s Evotec has licensed a portfolio of small molecules and biologics from its CureBeta regenerative diabetes collaboration with Harvard University and the Howard Hughes Medical Institute to Johnson & Johnson’s Janssen Pharmaceuticals subsidiary. Janssen will pay US$8 M upfront plus approximately US$200–300 M in milestone payments and royalties for each successfully commercialised product resulting from the collaboration. Evotec and Harvard will share all of the payments according to pre-agreed terms.